Novo Nordisk’s Concizumab Could Be First In New Class For Hemophilia
TFPI Inhibitors Have 20 Years Of Bad History
Executive Summary
Phase III data for the drug showed strong efficacy among hemophilia A and B patients with inhibitors. The drug’s approval would help drive continued segmentation of the hemophilia market.